Since its creation, MATWIN relies on a large network of public and private partners all committed to develop oncology innovation.
Large pharmaceutical and diagnostic companies are involved in this original programme since its creation. Their ambitious challenge is to ensure a public-private partnership within oncology innovation and to highlight French research excellence in this area.
Thirteen international major groups (Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, MSD, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi) are now part of the MATWIN adventure and are actively involved in the programme. Thanks to their support, MATWIN offers them access to a national showcase of oncology R&D in France.
A network of associated partners
Since the construction of the program, MATWIN has developed a strong network of partners specifically involved in supporting innovation in oncology. Throughout the year, specific structures such as Cancéropôles, SIRICs, incubators, competitiveness clusters and technology transfer offices (Inserm Transfert, CNRS Innovation, SATT, etc.) help the MATWIN platform to identify projects with high transfer potential on the territory. They accompany and follow the projects throughout the MATWIN process, fully benefiting from experts feedback and therefore optimizing the project valorisation process. The value chain thus created by MATWIN benefits the entire ecosystem.